At Patheon, we deliver enhanced simplicity, speed, and quality to clients across the pharmaceutical and biotechnology sectors. As a leading global provider of pharmaceutical development and manufacturing services, we provide a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle.
Type
Public
HQ
Durham, US
Founded
1974
Size (employees)
9,100 (est)+4%
Patheon was founded in 1974 and is headquartered in Durham, US

Patheon Office Locations

Patheon has an office in Durham
Durham, US (HQ)
300 4815 Emperor Blvd

Patheon Data and Metrics

Patheon Financial Metrics

Patheon's revenue was reported to be $1 b in FY, 2013
USD

Revenue (FY, 2013)

1 b

Gross profit (FY, 2013)

249.1 m

Gross profit margin (FY, 2013), %

24%

Net income (FY, 2013)

(35.9 m)

EBIT (FY, 2013)

33.9 m

Market capitalization (18-Aug-2017)

5.1 b

Cash (31-Oct-2013)

61.6 m

EV

5.7 b
Patheon's current market capitalization is $5.1 b.
USDFY, 2013

Revenue

1 b

Cost of goods sold

774 m

Gross profit

249.1 m

Gross profit Margin, %

24%

EBIT

33.9 m

EBIT margin, %

3%

Pre tax profit

(42.3 m)

Net Income

(35.9 m)
USDFY, 2013

Cash

61.6 m

Accounts Receivable

191.3 m

Inventories

137.8 m

Current Assets

415.7 m

Goodwill

48.5 m

Total Assets

1.1 b

Total Debt

606 m

Current Liabilities

246.9 m

Retained Earnings

(514.5 m)

Total Equity

126.4 m

Debt to Equity Ratio

4.8 x

Debt to Assets Ratio

0.6 x

Financial Leverage

8.5 x
USDFY, 2013

Depreciation and Amortization

48.4 m

Cash From Operating Activities

13 m

Cash From Financing Activities

306.9 m

Interest Paid

42.1 m
Y, 2013

EV/EBIT

166.9 x

EV/CFO

435.3 x

Debt/Equity

4.8 x

Debt/Assets

0.6 x

Financial Leverage

8.5 x

Patheon Market Value History

Patheon Median Salaries

Source: 16 public H-1B filings from Patheon

Traffic Overview of Patheon

Patheon Online and Social Media Presence

Patheon News and Updates

Thermo Fisher Scientific is buying drug-ingredients maker Patheon for $7.2 billion (TMO)

The biotech company Thermo Fisher Scientific has agreed to buy the drug-ingredients maker Pantheon for $7.2 billion.  In a statement on Monday, Thermo Fisher said it will acquire all outstanding Pantheon shares for $35 apiece in cash. The deal's value includes approximately …

Patheon Company Life and Culture

You may also be interested in